-

Shareholder Alert: Robbins LLP Announces That Bit Digital, Inc. (BTBT) is Being Sued for Misleading Shareholders

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Bit Digital, Inc. (NASDAQ: BTBT) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 21, 2020 and January 11, 2021. Bit Digital is a holding company that purportedly engages in the bitcoin mining business through its wholly owned subsidiaries in the U.S. and Hong Kong.

If you suffered a loss due to Bit Digital Inc.'s misconduct, click here.

Bit Digital, Inc. (BTBT) Misled Shareholders About Its Bitcoin Mining Operations

According to the complaint, on December 21, 2020, Bit Digital announced its revised financial results for the third quarter 2020. The Company indicated that its "number of miners was 22,869, with 16,865 miners acquired in the third quarter 2020." However, Bit Digital overstated the extent of it bitcoin mining operation.

On July 11, 201, analyst J Capital Research issued a report alleging that Bit Digital operates "a fake crypto currency business" "designed to steal funds from investors." Although the Company claims "it was operating 22,869 bitcoin miners in China," J Capitl alleged that this "is simply not possible" and stated that "[w]e verified with local governments supposedly hosting the BTBT mining operation that there are no bitcoin miners there." On this news, the price of Bit Digital shares fell $6.27, or 25%, to close at $18.76 per share on January 11, 2021. The stock has yet to recover.

If you purchased shares of Bit Digital, Inc. (BTBT) between December 21, 2020 and January 11, 2021, you have until March 22, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Workhorse Group, Inc. settles or to receive free alerts about company executives engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom